Summit Therapeutics Inc [SMMT] stock is trading at $17.82, up 1.02%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SMMT shares have gain 7.61% over the last week, with a monthly amount drifted -7.33%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Barclays started tracking the stock with Underweight rating on September 17, 2025, and set its price target to $13. On September 04, 2025, Guggenheim initiated with a Buy rating and assigned a price target of $40 on the stock. Piper Sandler started tracking the stock assigning a Neutral rating and suggested a price target of $21 on August 19, 2025. UBS initiated its recommendation with a Buy and recommended $30 as its price target on July 01, 2025. Leerink Partners started tracking with a Underperform rating for this stock on June 11, 2025, and assigned it a price target of $12. In a note dated March 26, 2025, Citigroup upgraded a Buy rating on this stock and boosted its target price from $23 to $35.
Summit Therapeutics Inc [SMMT] stock has fluctuated between $15.55 and $36.91 over the past year. Currently, Wall Street analysts expect the stock to reach $23 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $17.82 at the most recent close of the market. An investor can expect a potential return of 29.07% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -3.52, Equity is -3.11 and Total Capital is -4.75. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.52 points at the first support level, and at 17.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.06, and for the 2nd resistance point, it is at 18.30.
Ratios To Look Out For
For context, Summit Therapeutics Inc’s Current Ratio is 3.80. Further, the Quick Ratio stands at 3.80, while the Cash Ratio is 3.68.
Transactions by insiders
Recent insider trading involved Xia Yu, Director, that happened on Oct 21 ’25 when 0.53 million shares were purchased. Co-Chief Executive Officer, DUGGAN ROBERT W completed a deal on Oct 21 ’25 to buy 26680.0 shares. Meanwhile, Co-Chief Executive Officer Zanganeh Mahkam bought 26680.0 shares on Oct 21 ’25.
